Scarica l'app Stockscreener
2.48
3.77%
0.09
Dopo l'orario di chiusura:
2.44
-0.04
-1.61%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACRS Giù?
Forum
Previsione
Precedente Chiudi:
$2.39
Aprire:
$2.5
Volume 24 ore:
2.88M
Relative Volume:
1.14
Capitalizzazione di mercato:
$265.41M
Reddito:
$31.25M
Utile/perdita netta:
$-88.48M
Rapporto P/E:
-1.9528
EPS:
-1.27
Flusso di cassa netto:
$-79.63M
1 W Prestazione:
-1.20%
1M Prestazione:
+0.00%
6M Prestazione:
+85.07%
1 anno Prestazione:
+113.79%
Intervallo 1D:
$2.36
$2.60
Intervallo di 1 settimana:
$2.28
$2.60
Portata 52W:
$0.9515
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Nome
Aclaris Therapeutics Inc
Settore
Industria
Telefono
484-324-7933
Indirizzo
701 LEE ROAD, WAYNE, PA
Confronta ACRS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
2.48 | 265.41M | 31.25M | -88.48M | -79.63M | -1.27 |
|
TMO
Thermo Fisher Scientific Inc
|
597.75 | 228.64B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
222.74 | 160.17B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
151.52 | 43.27B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
201.36 | 36.55B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
422.05 | 34.56B | 3.84B | 866.24M | 792.60M | 10.37 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-11-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-19 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | Iniziato | Evercore ISI | Outperform |
| 2022-12-14 | Iniziato | Stifel | Buy |
| 2022-12-01 | Iniziato | Goldman | Buy |
| 2022-10-06 | Iniziato | BTIG Research | Buy |
| 2021-07-23 | Ripresa | Jefferies | Buy |
| 2021-06-15 | Iniziato | Piper Sandler | Overweight |
| 2021-04-21 | Iniziato | H.C. Wainwright | Buy |
| 2019-10-22 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | Iniziato | SVB Leerink | Outperform |
| 2018-03-28 | Ripresa | Leerink Partners | Outperform |
| 2018-02-09 | Iniziato | Guggenheim | Buy |
| 2017-06-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-11-29 | Iniziato | Leerink Partners | Outperform |
| 2016-09-30 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-06-10 | Iniziato | Guggenheim | Buy |
| 2015-11-02 | Iniziato | Citigroup | Buy |
| 2015-11-02 | Iniziato | Jefferies | Buy |
Mostra tutto
Aclaris Therapeutics Inc Borsa (ACRS) Ultime notizie
Aclaris Therapeutics Forms Scientific Advisory Board with Renowned Pulmonology Experts - MSN
Aclaris Therapeutics (NASDAQ:ACRS) Rating Increased to Strong-Buy at Cantor Fitzgerald - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 12.7% in January - Defense World
Aclaris Therapeutics forms new Scientific Advisory Board - MSN
StockNews.com Downgrades Aclaris Therapeutics (NASDAQ:ACRS) to Sell - Defense World
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board - GlobeNewswire
Aclaris Therapeutics forms new Scientific Advisory Board By Investing.com - Investing.com Nigeria
Aclaris Therapeutics Appoints Marianne Mann and Zuzana Diamant to Scientific Advisory Board - citybiz
Assenagon Asset Management S.A. Acquires 211,585 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Purchased by Assenagon Asset Management S.A. - MarketBeat
Cantor Fitzgerald Comments on ACRS FY2025 Earnings - Defense World
Cantor Fitzgerald Weighs in on ACRS FY2025 Earnings - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 12.7% in December - MarketBeat
Hair Treatment Drug Market Is Booming Worldwide | 3S Bio, Inc.,AbbVie,Aclaris Therapeutics, Inc.,Cipla, Inc. - openPR
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $11.00 Average Target Price from Brokerages - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Sold by Jane Street Group LLC - MarketBeat
Jane Street Group LLC Reduces Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics Highlights Drug Progress and Financial Strength - TipRanks
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Geode Capital Management LLC Grows Stock Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics Awards Stock Options to Attract Top Talent - MSN
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Hair Loss Treatment Market Is Booming Worldwide 2024-2031 | Viviscal, Cipla Inc., Aclaris Therapeutics - openPR
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Sold by State Street Corp - Defense World
Aclaris sells OLUMIANT royalties and milestones to OMERS life sciences - MSN
HC Wainwright & Co. Upgrades Aclaris Therapeutics (ACRS) - MSN
ACRS LOSS NOTICE: ROSEN, A LEADING FIRM, Announces Filing of Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the FirmACRS - AccessWire
INVESTOR ALERTAclaris Therapeutics, Inc. (ACRS)Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: September 30, 2019 - AccessWire
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Update - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 27.4% in December - MarketBeat
Research Analysts Issue Forecasts for ACRS FY2024 Earnings - Defense World
HC Wainwright Has Bullish Estimate for ACRS FY2024 Earnings - MarketBeat
Aclaris Therapeutics shares upgraded to Buy on strong growth potential in AD and asthma - Investing.com Nigeria
Aclaris Therapeutics shares upgraded to Buy on strong growth potential in AD and asthma By Investing.com - Investing.com South Africa
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded to Buy at HC Wainwright - Defense World
HighTower Advisors LLC Trims Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
This Weyerhaeuser Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday - Benzinga
Pony AI, Thermo Fisher initiated: Wall Street’s top analyst calls - Nasdaq
HC Wainwright Upgrades Aclaris Therapeutics (NASDAQ:ACRS) to "Buy" - MarketBeat
Analysts Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target at $8.80 - Defense World
Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Target Price at $8.80 - MarketBeat
Fmr LLC Cuts Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Financial Review: Aclaris Therapeutics (NASDAQ:ACRS) versus Theratechnologies (NASDAQ:THTX) - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Growth in Short Interest - Defense World
Aclaris Therapeutics Announces New Employee Stock Grants Under 2024 Inducement Plan - MSN
Aclaris Therapeutics Inc Azioni (ACRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.69%
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):